Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Conditions
Interventions
nalbuphine HCl ER tablets 60 mg BID
nalbuphine HCl ER tablets 120mg BID
+1 more
Locations
47
United States
Nephrology Associates PC
Birmingham, Alabama, United States
University South Alabama Medical Center
Mobile, Alabama, United States
Arizona Kidney Disease and Hypertension Center
Phoenix, Arizona, United States
U.S. Renal Care Inc
Pine Bluff, Arkansas, United States
North America Research Institute
Azusa, California, United States
Pegasus Dialysis, LLC
Bakersfield, California, United States
Start Date
June 1, 2014
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
May 21, 2025
NCT05689463
NCT06506240
NCT05500794
NCT06488742
NCT07380113
NCT06737484
Lead Sponsor
Trevi Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions